InsiderClue
Stocks · Health care · Pharmaceutical Preparations

AN2 Therapeutics, Inc.

ANTX Clue Score37
United States Fiscal year ends December CIK 0001880438
$4.40 -5.98% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.40 −69.99% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 25 Mar 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2021Operating income−21.6Net income−21.5EPS, diluted−10.64Fiscal year 2022Operating income−42.3Net income−41.0EPS, diluted−2.79Fiscal year 2023Operating income−69.6Net income−64.7EPS, diluted−2.74Fiscal year 2024Operating income−56.8Net income−51.3EPS, diluted−1.72Fiscal year 2025Operating income−38.1Net income−35.2EPS, diluted−1.16
FY2021FY2022FY2023FY2024FY2025
Operating income −21.6 −42.3 −69.6 −56.8 −38.1
Net income −21.5 −41.0 −64.7 −51.3 −35.2
Growth
EPS, diluted −10.64 −2.79 −2.74 −1.72 −1.16

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2021Operating cash flow−20.5Fiscal year 2022Operating cash flow−33.5Fiscal year 2023Operating cash flow−53.3Fiscal year 2024Operating cash flow−49.3Fiscal year 2025Operating cash flow−29.8
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −20.5 −33.5 −53.3 −49.3 −29.8

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash12.1Shareholders’ equity−47.4Fiscal year 2022Cash27.2Shareholders’ equity95.4Fiscal year 2023Cash15.6Shareholders’ equity124.7Fiscal year 2024Cash21.4Shareholders’ equity81.8Fiscal year 2025Cash19.9Shareholders’ equity53.1
FY2021FY2022FY2023FY2024FY2025
Cash 12.1 27.2 15.6 21.4 19.9
Shareholders’ equity −47.4 95.4 124.7 81.8 53.1

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−20.5 −33.5 −53.3 −49.3 −29.8
Growth
Investment
−50.0 −21.8 −43.3 54.6 28.3
Financing
78.5 70.4 85.0 0.4 0.1

Capital expenditure, dividends and buybacks are shown as money out, so negative.